TABLE 1.
Summary of Clinical Information for Transplant Cases Categorized by Allograft MaS status.
| Covariates | MaS grafts | Non-MaS grafts | p-valuea |
| Number (%) | 35 (42.7) | 47 (57.3) | NA |
| Recipient factor (R) | |||
| Age (R, years) | 49 (34−54) | 50 (43−56) | 0.12 |
| Gender (R, M,%) | 30 (85.7) | 39 (83.0) | 0.74 |
| BMI (R, kg/m2) | 23.1 ± 2.7 | 23.8 ± 3.2 | 0.34 |
| Blood Type (R) | 0.98 | ||
| A-type n (%) | 15 (42.9) | 18 (38.3) | |
| B-type n (%) | 4 (11.4) | 6 (12.8) | |
| O-type n (%) | 14 (40) | 20 (42.6) | |
| AB-type n (%) | 2 (5.7) | 3 (6.4) | |
| Diabetes (R, N,%) | 3 (8.6) | 7 (14.9) | 0.39 |
| Pre-operative AFP (R, ng/ml) | 30.4 (4.9−551.4) | 16.1 (5.6−139.0) | 0.44 |
| HBV infectors (R, N,%) | 24 (68.6) | 39 (83.0) | 0.13 |
| MELD score (R) | 33 (28−40)∗ | 33 (26−40) | 0.70 |
| Child–pugh score (R) | 10 (9−11) | 11 (10−12) | 0.11 |
| Donor factor (D) | |||
| Age (D, years) | 45 (31−51) | 44 (36−53) | 0.80 |
| Gender (D, M,%) | 29 (82.9) | 40 (85.1) | 0.78 |
| BMI (D, kg/m2) | 23.8 ± 2.8 | 22.9 ± 2.5 | 0.13 |
| Blood type (D) | 0.60 | ||
| A-type n (%) | 13 (37.1) | 14 (29.8) | |
| B-type n (%) | 5 (14.3) | 7 (14.9) | |
| O-type n (%) | 13 (37.1) | 19 (40.4) | |
| AB-type n (%) | 4 (11.4) | 7 (14.9) | |
| HBV infectors (D, N,%) | 6 (17.1) | 5 (10.6) | 0.39 |
| HCV infectors (D, N,%) | 6 (17.1) | 0 (0) | NA |
| Pre-donation blood test (D) | |||
| D-Potassium (mmol/L) | 3.7 (3.4−4.1) | 4 (3.7−4.6) | 0.02 |
| D-Sodium (mmol/L) | 145.9 (139.0−152.0) | 145.8 (138.1−153.1) | 0.79 |
| D-ALT (U/L) | 44.0 (25.0−74.0) | 39.4 (25−62) | 0.55 |
| D-TB (μmol/L) | 14.8 (10.4−21.4) | 19.3 (11−27) | 0.15 |
| D-CR (μmol/L) | 87.0 (55.0−160.0) | 86.3 (61.0−151.6) | 0.82 |
| D-BUN (mmol/L) | 7.6 (5.5−10.9) | 8.6 (5.0−11.6) | 0.57 |
| Donation type (DBD/DCD/DBCD) | 0.25 | ||
| DBD (N, %) | 12 (34.2) | 10 (21.3) | |
| DCD (N, %) | 16 (45.7) | 30 (63.8) | |
| DBCD (N, %) | 7 (20.0) | 7 (14.9) | |
| Cause of Death (TBI/Stroke/Others) | 17/16/2 | 23/20/3 | 0.98 |
| ECMO use | 0 | 0 | NA |
| Graft factor (G) | |||
| Steatosis Severity (%) | 15 (5−25) | 10 (5−18.8) | <0.01 |
| CIT (min) | 646 (542−744) | 652 (567−743) | 0.68 |
| WIT (min) | 5 (0−10)∗ | 9 (5−12) | 0.03 |
| Surgery (S) | |||
| Indication for LT | 0.65 | ||
| Liver Cirrhosis n (%) | 13 (37.1) | 22 (46.8) | |
| Liver Failure n (%) | 10 (28.6) | 7 (14.9) | |
| PBC/PSC n (%) | 2 (5.7) | 2 (4.3) | |
| Liver Cancer n (%) | 17 (48.6) | 19 (40.4) | |
| Others n (%) | 1 (2.9) | 2 (4.3) | |
| Post-LT Peak TB level (mg/dL) | 205.9 (106−386) | 225 (138−387) | 0.58 |
| Post-LT Peak ALT Level (IU/L) | 2626 (2027−3694) | 2401 (1972−3075) | 0.35 |
| Post-LT Peak AST level (IU/L) | 6576 (4673−13638) | 6049 (3665−8745) | 0.27 |
| EAD occurrence n (%) | 22 (62.9) | 30 (63.8) | 0.93 |
| PNF occurrence n (%) | 4 (11.4) | 6 (12.8) | 0.86 |
| Blood Transfusion during LT | 745 (630−1220) | 775 (510−1020) | 0.65 |
| pRBC (U) | 4.5 (2.0−8.0) | 5.0 (2.0−9.0) | 0.71 |
| FFP (ml) | 3000 (0−3500) | 3000 (1500−4000) | 0.48 |
| PCC (U) | 2000 (0−3000) | 1750 (75−3000) | 0.19 |
| FIB (g) | 5 (0−7.5) | 5 (2−10) | 0.44 |
| ALB (g) | 115 (30−150) | 125 (75−150) | 0.50 |
| Blood Loss (ml) | 1500 (1000−2500) | 1200 (800−2000) | 0.12 |
| Surgical Duration (mins) | 310 (275−375) | 302.4 (260−339) | 0.40 |
| ICU stay (days) | 12.8 (7.6−17) | 13 (7.6−18) | 0.97 |
| Length of post−LT hospitalization (d) | 29 (19−39) | 26 (12−37) | 0.72 |
| Year of LT | 0.07 | ||
| 2015−2016 (n,%) | 7 (20) | 20 (42.6) | |
| 2017−2019 (n,%) | 28 (80) | 27 (57.4) | |
| Time from LT to the end of follow-up survey (days) | 616 (510−885) | 894 (624−1670) | 0.02 |
*Represented significant difference across different groups; a represented. acomparison was performed by one-way ANOVA for quantitative data in symmetrical distribution; by Mann−Whitney U-test for quantitative data in asymmetrical distribution; by Chi-square test for count data. D, donor; DBCD, donation after brain and cardiac death; DBD, donation after brain death; DCD, donation after cardiac death; EAD, early allograft dysfunction; ECMO, extracorporeal membrane oxygenation; FFP, fresh frozen plasma; FIB, fibrinogen; G, graft; HBV, hepatitis B virus; HCV, hepatitis C virus; ICU, intensive care unit; LT, liver transplantation; M, male; MaS, macrosteatosis; MELD, model for end-stage liver disease; PBC, primary biliary cholangitis; PCC, prothrombin complex concentrate; PNF, primary non-function; PSC, primary sclerosing cholangitis; R, recipient; RBC, red blood cell; TB, total bilirubin; TBI, traumatic brain injuries.